The pharmaceutical companies Bayer and Novartis have both shown interest in Pfizer’s veterinary medicine division. The potential purchase price is supposed to range from 15 to 20 billion dollars.
Instead of selling the division, however, Pfizer would also consider splitting it off to avoid an increased tax burden. While the group is weighing its options, Pfizer has not yet made a decision regarding the future of the division which turned over about 4 billion dollars in 2011.
[ilink url=“http://www.kma-online.de/nachrichten/politik/id__26720___view.html“]link to source (kma-online)[/ilink]